Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01542879
Recruitment Status : Recruiting
First Posted : March 2, 2012
Last Update Posted : April 18, 2018
Information provided by (Responsible Party):
Heike E Daldrup-Link, Stanford University

Brief Summary:
A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if newer imaging tests referred to as whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The advantage of the new imaging test is that it is associated with no or significantly reduced radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole body MR and PET/MR will be compared with that of the conventional, standard imaging studies for tumor detecting.

Condition or disease Intervention/treatment Phase
Cancer Procedure: WB-DW-MR scan Procedure: 18F-FDG PET scan Drug: Ferumoxytol Not Applicable

Detailed Description:

New developments in magnetic resonance (MR) imaging technology provide an alternative to radiographic staging techniques. Novel whole body (WB) diffusion weighted MR scans (WB-DW-MR) provide a very high tumor-to background contrast, similar to 18F-FDG PET scans. Therefore, this study was designed to compare the sensitivity of whole-body MR and 18F-FDG PET for detecting metastatic disease in children with malignant lymphomas and malignant sarcomas. Recently, integrated whole body PET/MRI technologies have been proposed as a compromise between radiation-free WB-DW MRI (which does not provide information about tumor metabolism) and PET/CT, which is associated with high radiation exposure.

Pediatric patients with a newly diagnosed malignant lymphoma, malignant sarcoma or other solid tumor, who are scheduled to undergo clinical imaging for tumor staging, will also undergo WB-DW-MR and integrated 18F-FDG PET/MR as a staging procedure prior to, during and after treatment. Following intravenous injection of ferumoxytol (Feraheme) and/or 18F-fluoro-deoxy-glucose (FDG), WB-DW-MR scans and integrated 18F-FDG PET/MR scans will be obtained simultaneously on a 3T PET/MR system with an acquisition time of 60-90 minutes. Very young patients who would need an anesthesia or sedation for this study will be excluded in order to keep this initial research exam minimally invasive. Two experienced pediatric radiologists will determine the presence, location and size of primary tumors and metastases separately for the WB-DW-MR, 18F-FDG PET/MR studies and 18F-FDG PET or PET/CT scans. The presence or absence of tumor lesions will be confirmed by histopathology or clinical and imaging follow-up over at least one year as the standard of reference.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.
Study Start Date : February 2012
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans
U.S. FDA Resources

Arm Intervention/treatment
Experimental: WB-DW-MR scan
simultaneous WB-DW-MR scan and 18F FDG PET scan
Procedure: WB-DW-MR scan
Other Name: Whole Body Diffusion Weighted MR scan
Procedure: 18F-FDG PET scan
Other Name: Fludeoxyglucose PET scan
Drug: Ferumoxytol
Other Name: feraheme

Primary Outcome Measures :
  1. comparison of sensitivity, specificity and accuracy of WB-DW-MR scans to 18 F-FDG-PET scans. [ Time Frame: The outcome will be measured after image acquisition ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age of less than 40 years
  • diagnosis of a malignant lymphoma or sarcoma
  • scheduled for or completed a PET or PET/CT tumor staging procedure.

Exclusion Criteria:

  • MR-incompatible metal implants
  • need of sedation
  • claustrophobia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01542879

United States, California
Stanford University Cancer Institute Recruiting
Stanford, California, United States, 94305
Contact: Kangla Tsung    650-725-8198   
Principal Investigator: Heike Daldrup-Link, MD         
Sub-Investigator: Andrew Quon         
Sub-Investigator: Neyssa Marina         
Sub-Investigator: Florette Kimberley Hazard         
Sub-Investigator: Dita Gratzinger         
Principal Investigator: Anne Muehe         
Sponsors and Collaborators
Heike E Daldrup-Link
Principal Investigator: Heike Daldrup-Link Stanford University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Heike E Daldrup-Link, Associate Professor of Radiology, Stanford University Identifier: NCT01542879     History of Changes
Other Study ID Numbers: PEDSVAR0017
IRB-20221 ( Other Identifier: Stanford IRB )
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: April 2018

Additional relevant MeSH terms:
Fluorodeoxyglucose F18
Ferrosoferric Oxide
Molecular Mechanisms of Pharmacological Action
Parenteral Nutrition Solutions
Pharmaceutical Solutions